Stock events for NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. stock has been impacted by several significant events. In January 2026, the stock experienced a 54% decline following a sales agreement announcement and a 103% surge due to merger speculation and a $6 million investment. The company completed a 1-for-5 reverse stock split in February 2026. In August 2025, NovaBay announced a one-time special cash dividend of $0.80 per share and leadership changes. In December 2024, NovaBay received an upgrade to a Zacks Rank #2 (Buy). The stock has demonstrated high volatility over the past year.
Demand Seasonality affecting NovaBay Pharmaceuticals, Inc.’s stock price
NovaBay Pharmaceuticals has experienced some demand seasonality for its products, particularly its Avenova eyecare line. The company reported record sales for Avenova products during Amazon Prime Day events, which typically occur in July. Additionally, NovaBay anticipated stronger sales performance in the fourth quarter of 2024, driven by the holiday season and a focus on the physician-dispensed channel.
Overview of NovaBay Pharmaceuticals, Inc.’s business
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing anti-infective solutions, historically focusing on eyecare, wound care, and skincare products. The company's major products included the Avenova brand for eyecare and NeutroPhase and PhaseOne for wound care. NovaBay completed the sale of its Avenova eyecare business in September 2024 and divested DERMAdoctor and PhaseOne assets in 2025. The company's core business revolved around its proprietary hypochlorous acid (HOCl) platform technology.
NBY’s Geographic footprint
NovaBay Pharmaceuticals, Inc. is headquartered in Emeryville, California, United States. The company has also sold its wound care products to distribution partners in China.
NBY Corporate Image Assessment
NovaBay Pharmaceuticals' Avenova-branded eyecare products demonstrated a positive reputation, achieving record sales during Amazon Prime Day events and maintaining a 4.5-star average rating across online channels. However, the company's reputation has been affected by strategic shifts, including the sale of its Avenova eyecare business in September 2024 and the divestiture of DERMAdoctor and PhaseOne assets in 2025. Management changes also occurred in August and October 2025, and the company is evaluating strategic alternatives.
Ownership
Major institutional and individual owners of NovaBay Pharmaceuticals, Inc. include R01 Fund LP, Framework Ventures Management LLC, David Elliot Lazar, BlackRock, Inc., The Vanguard Group, Inc., Geode Capital Management, L.L.C., State Street Corp, Northern Trust Corp, Goldman Sachs Group Inc, Charles Schwab Investment Management Inc, Jane Street Group, Llc, Susquehanna International Group, Llp, and C2C Wealth Management, LLC. As of late 2025 and early 2026, institutional shareholders held 23.25% to 24.18% of NovaBay Pharmaceuticals' stock.
